Tools4Patient’s Placebell©™ technology has been selected as a finalist in the 2019 Clinical Trials Innovation Challenge sponsored by IQVIA, Lundbeck, and LEO Innovation Lab.
“Sensory Profiles and stratification of neuropathic pain patients based on the neuropathic pain symptom inventory (NPSI)” presented at the 2019 European Pain Federation EFIC Conference.
This study aimed to identify specific sensory phenotypes of peripheral neuropathic pain patients that could predict treatment response based on pain symptoms assessed by the Neuropathic Pain Symptom Inventory (NPSI).
Placebell©™ technology designed to limit the negative impact of the placebo effect in clinical trials.
While drug developers have been struggling with the placebo response for decades, Placebell©™ is the first commercially available technology that enables scientists to control for the placebo response in clinical studies. Tools4Patient (T4P) launched Placebell©™ in late 2017,
The commercial launch of Placebell©™ for peripheral neuropathic pain in October 2017 has increased interest from biopharma industry stakeholders in T4P’s low-risk validated technology.
Following the commercial launch of Placebell©™ in peripheral neuropathic pain in October 2017 and the initiation of the validation of Placebell©™ in osteoarthritis in August 2017,